01 Rising Demand for Multifunctional Excipients The use of multifunctional excipients is gaining strong traction across pharmaceutical manufacturing. Companies such as BASF SE and Evonik Industries AG are developing excipients that combine multiple functionalities such as binding, coating, and stabilization within a single formulation component. This trend supports cost efficiency, simplifies manufacturing processes, and enhances product performance, aligning with the industry’s shift toward efficient and innovative drug formulation technologies.
02 Shift from Synthetic to Bio-Based Excipients A major trend in the pharmaceutical excipients market is the ongoing shift from synthetic to bio-based excipients, driven by rising environmental concerns and stricter sustainability regulations. Manufacturers such as Roquette Frères and Ashland Inc. are increasingly replacing petrochemical-derived ingredients with plant-based, renewable alternatives. This transition supports eco-friendly manufacturing, reduces carbon emissions, and aligns with the pharmaceutical industry’s broader commitment to sustainable solutions.
June 2026 BASF expanded its pharmaceutical excipients portfolio with new functional ingredients and formulation solutions for advanced drug delivery applications. The company focused on supporting pharmaceutical manufacturers with improved excipient performance and formulation flexibility.
March 2026 Evonik expanded its pharmaceutical excipients and drug delivery solutions with new formulation technologies for oral and injectable medicines. The developments support complex drug formulations and improved therapeutic delivery.
January 2026 Roquette expanded its pharmaceutical excipients portfolio with new solutions based on plant-derived ingredients. The company continued developing excipients for tablets, capsules, and specialty pharmaceutical formulations.
October 2025 Lubrizol expanded its pharmaceutical excipients business with advanced polymers and formulation ingredients for controlled-release drug delivery. The initiatives support pharmaceutical companies developing innovative dosage forms.